Can tofacitinib/Shangjie treat skin diseases?

Although Tofacitinib/Shangjie (Tofacitinib) was first widely recognized for the treatment of rheumatoid arthritis, its immunomodulatory mechanism is also of great value in skin-related diseases, so it is often misunderstood as "whether it specializes in treating skin diseases." Judging from the scope of global approval, tofacitinib is currently mainly suitable for diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis. Among them, psoriatic arthritis is an immune disease involving skin manifestations and is the most representative indication of tofacitinib in the skin field.

Psoriatic arthritis is a type of immune disease characterized by skin plaques, dactylitis, and joint pain. Its onset is related to the JAK pathway. Therefore, by inhibiting inflammatory factor signals, tofacitinib can help reduce symptoms such as thickening of skin lesions, joint pain, and morning stiffness. Overseas real-world studies also pointed out that tofacitinib can provide additional room for symptom improvement in some patients who are poorly controlled by external medications or traditional DMARDs, becoming a type of "skin + synchronized control" option.

In addition, tofacitinib’s research in the field of skin immunity is not limited to psoriatic arthritis. In some countries, there are studies exploring its prospects in chronic dermatitis, alopecia areata, atopic dermatitis and other diseases. Although not all of these indications have been formally approved by regulatory authorities, overseas studies continue to emphasize the importance of the JAK pathway in skin immune responses, making tofacitinib one of the high-profile targeted drugs in skin disease research. Some dermatologists believe that the advantage of tofacitinib lies in systemic immune regulation, which is suitable for people with complex and large-scale skin inflammatory diseases or joint problems.

Reference materials: https://www.xeljanz.com/